Wen-Cherng Lee

USPTO Granted Patents = 25 (Patent Applications = 8)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 119(Granted Patents)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

patents

6. 1 out of 36

Millenium Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2001-2018

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10081646 - Heterobicyclic sphingosine 1-phosphate analogs (2018-09-25),

2. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

3. 9873693 - Methods of treatment using pyridinonyl PDK1 inhibitors (2018-01-23),

4. 9708353 - Heterobicyclic sphingosine 1-phosphate analogs (2017-07-18),

5. 9546165 - Heterocyclic compounds useful as PDK1 inhibitors (2017-01-17),

6. 9181191 - Heterobicyclic sphingosine 1-phosphate analogs (2015-11-10),

7. 8778977 - Pyridinonyl PDK1 inhibitors (2014-07-15),

8. 8546359 - Bicyclic aryl sphingosine 1-phosphate analogs (2013-10-01),

9. 8349849 - Heterobicyclic sphingosine 1-phosphate analogs (2013-01-08),

10. 8269043 - Bicyclic aryl sphingosine 1-phosphate analogs (2012-09-18),

11. 7691865 - Pyrazolopyridines and methods of making and using the same (2010-04-06),

12. 7612094 - Tri-substituted heteroaryls and methods of making and using the same (2009-11-03),

13. 7196112 - Cell adhesion inhibitors (2007-03-27),

14. 7034043 - Cell adhesion inhibitors (2006-04-25),

15. 7001921 - Cell adhesion inhibitors (2006-02-21),

Title: Innovator Spotlight: Wen-Cherng Lee

Introduction

Wen-Cherng Lee, a notable inventor based in Lexington, MA, has made significant contributions to the field of biomedical research and pharmaceutical innovations. With an impressive portfolio of 25 patents, he has focused on areas critical to the development of new therapeutic agents.

Latest Patents

Among his notable recent innovations are two groundbreaking patents. The first, titled "Heterobicyclic sphingosine 1-phosphate analogs," provides compounds that exhibit agonist activity at one or more of the S1P receptors. These sphingosine analogs, upon phosphorylation, can effectively act as agonists, presenting potential therapeutic pathways. The second patent, "Heterocyclic compounds useful as PDK1 inhibitors," offers compounds that serve as inhibitors of PDK1. This invention also discusses useful compositions and methods for treating diseases mediated by PDK1, highlighting the potential impact of these compounds on patient care.

Career Highlights

Wen-Cherng Lee's career is distinguished by his roles in prominent companies such as Biogen and Biogen Idec MA Inc. His work in these organizations has allowed him to be at the forefront of innovative research, driving forward the development of novel pharmaceuticals.

Collaborations

Throughout his career, Lee has collaborated with esteemed colleagues, including Daniel M. Scott and Edward Yin-Shiang Lin. These partnerships have significantly enhanced the research outcomes and innovations surrounding his patents, showcasing the importance of collaborative efforts in advancing scientific knowledge.

Conclusion

Wen-Cherng Lee's contributions to innovation in the biomedical field are profound. His extensive patent portfolio demonstrates a commitment to enhancing therapeutic options for various health conditions, positioning him as a key figure in pharmaceutical innovation. As he continues to expand his research, the impact of his work remains significant in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.